surmount-1 tirzepatide weight loss percent 72 weeks (ZEPBOUND) Approved for Chronic Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Tirzepatide as Compared with Semaglutide

The Bottom Line Success on GLP-1 medications isn't just about taking your weekly injectionit's about pairing that medication with a strategic nutrition approach that preserves muscle, minimizes side effects, and sets you up for long-term sustainable weight loss

It is not a traditional healthcare avenue for patients to seek treatment outside the established clinical guidelines of Weight Management

Would you like a sample intake plan you can use with your clinician?

If your provider recommends any form of tirzepatide, you want to know what tirzepatide side effects are, along with its warnings, contraindications, and potential drug interactions

Its extended half-life allows for once-weekly research protocols, and ongoing investigation spans cardiometabolic health, hepatic fat metabolism, and sleep-disordered breathing